NCT02669511View on ClinicalTrials.gov

PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 12, 2015

Primary Completion Date

January 12, 2018

Study Completion Date

January 12, 2018

Conditions
Primary Central Nervous System Lymphoma
Interventions
DRUG

PQR309

Oral PQR309, 80mg or 60mg daily or intermittent dosing

Sponsors
All Listed Sponsors
lead

PIQUR Therapeutics AG

INDUSTRY